Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

The Lancet Oncology

Volumn 12, Issue 5, 2011, Pages 451-459

  Denham, James W ^a   Steigler, Allison ^a   Lamb, David S ^b   Joseph, David ^c   Turner, Sandra ^d   Matthews, John ^e   Atkinson, Chris ^f   North, John ^g   Christie, David ^h   Spry, Nigel A ^c   Tai, Keen Hun ⁱ   Wynne, Chris ^f   D'Este, Catherine ^j  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b WELLINGTON HOSPITAL   (New Zealand)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

^f St Georges Cancer Care Centre   (New Zealand)

^g DUNEDIN HOSPITAL   (New Zealand)

^h Premion   (Australia)

ⁱ PETER MACCALLUM CANCER CENTRE   (Australia)

^j UNIVERSITY OF NEWCASTLE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; EVENT FREE SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RADIATION DOSE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEMINAL VESICLE; SHORT COURSE THERAPY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; AUSTRALIA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FLUTAMIDE; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEW ZEALAND; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; TIME FACTORS; TREATMENT OUTCOME;

EID: 79955470908     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70063-8     Document Type: Article

References (40)

1. Granfors T, Modig H, Damber J-E, Tomic R Long-term follow-up of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol 2006, 176:544-547.
2. Pilepich MV, Winter K, Lawton C, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290.
3. Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001, 50:1243-1252.
4. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005, 6:841-850.
5. D'Amico AV, Chen M-H, Renshaw AA, Loffredo M, Kantoff PW Androgen suppression and radiation vs radiation alone for prostate cancer. JAMA 2008, 299:289-295.
6. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360:103-108.
7. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337:295-300.
8. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of Radiation Therapy Oncology Group Protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26:2497-2504.
9. Pirl WF, Siegel GI, Goode MJ, Smith MR Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psycho-Oncology 2002, 11:518-523.
10. Pickles T, Agranovich A, Berthelet E, et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 2002, 94:362-367.
11. Salminen EK, Portin RI, Kockinen A, Helenius H, Nurmi M Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Can Res 2004, 10:7575-7582.
12. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997, 79:933-941.
13. Potosky AL, Reeve BB, Glegg LX, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002, 94:430-437.
14. Galvao DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 2009, 12:198-203.
15. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154-164.
16. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006, 24:3979-3983.
17. Freedland SJ, Eastham J, Shore N Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 2009, 12:333-338.
18. FDA drug safety communication: update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases US Department of Health & Human Services, (accessed Feb 15, 2011). http://www.fda.gov/Drugs/DrugSafety/ucm229986.htm.
19. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
20. Steigler A, Mameghan H, Lamb D, et al. A quality assurance audit: phase III trial of maximal androgen deprivation in prostate cancer (TROG 96.01). Australasian Radiol 2000, 44:65-71.
21. Kron T, Hamilton C, Roff M, Denham JW Dosimetric intercomparison for two Australasian clinical trials using an anthropomorphic phantom. Int J Radiat Oncol Biol Phys 2002, 52:566-579.
22. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. JAMA 1998, 280:969-974.
23. Roach M, Lu J, Pilepich MV, et al. Predicting long-term survival and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000, 47:617-627.
24. Fine JP, Gray RJ A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
25. King CR, Kapp DS Radiotherapy after prostatectomy: is the evidence for dose escalation out there?. Int J Radiat Oncol Biol Phys 2008, 71:346-350.
26. Denham JW, Steigler A, Wilcox C, et al. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol 2008, 9:1058-1068.
27. Lamb DS, Denham JW, Mameghan H, et al. Acceptability of short term neo-adjuvant deprivation in patients with locally advanced prostate cancer. Radiother Oncol 2003, 68:255-267.
28. Christie DRH, Denham JW, Steigler A, et al. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiother Oncol 2005, 77:117-125.
29. Capp A, Inostroza-Ponta M, Bill D, et al. Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial. Radiother Oncol 2008, 90:400-407.
30. Bolla M, De Reijke TM, van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527.
31. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005, 23:7897-7903.
32. McGowan D, Hunt D, Jones C, et al. Effect of short-term endocrine therapy prior to and during radiation therapy on overall survival in patients with T1b-T2b adenocarcinoma of the prostate and PSA equal to or less than 20: initial results of RTOG 94-08. ASCO Genitourinary Cancers Symposium; San Francisco, CA, USA; March 5-7, 2010. Abstr 6.
33. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010, 11:1066-1073.
34. TROG 03.04 - Randomised trial investigating the effect on survival and PSA control of different durations of adjuvant androgen deprivation in association with definitive radiation treatment for localised carcinoma of the prostate (RADAR) TROG Clinical Trials Summary, (accessed Feb 15, 2011). http://www.ranzcr.edu.au/affiliatedgroups/trog/healthprofessionals/hptrials/open/TROG_0304.cfm.
35. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24:1990-1996.
36. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487.
37. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M D Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
38. Zietman AL, DeSilvio M, Slater JD, et al. Comparison of convention-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 2005, 294:1233-1239.
39. Al-Mamgani A, Lebesque JV, Heemsbergen WD, et al. Controversies in the treatment of high-risk prostate cancer-what is the optimal combination of hormonal therapy and radiotherapy: a review of literature. Prostate 2010, 70:701-709.
40. Kollmeier MA, Zelefsky MJ What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?. Nat Clin Pract Urol 2008, 5:584-585.